Étude du passage de la γ-globuline marquée à travers le placenta humain

Pan, R. Martin Du; Wenger, Paul Eugène Etienne; Koechli, S; Scheidegger, J J; Roux, Julie

doi:10.1016/0009-8981(59)90090-7

Cited by 30 publications

(3 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, the average half-life of the labeled 7 S 72-globulin preparation in the pregnant women studied was 20.5 days, a value that agrees well with the average half-life of 23 days obtained by Cohen and Freeman (37) for radioiodinated 7 S y2-globulin in normal adults, the protein in the latter study being isolated by DEAE cellulose column chromatography and radioiodinated by the iodine monochloride method (38). The half-life of transferrin in this study was (42) similarly observed that radioiodinated 7 S y2-globulin rapidly appears in the human fetus after injection of the protein into the mother and that the steady state is reached only slowly.…”

Section: Discussionsupporting

confidence: 90%

The Selectivity of the Human Placenta in the Transfer of Plasma Proteins From Mother to Fetus

Gitlin¹,

Kumate²,

Urrusti³

et al. 1965

Obstetrical & Gynecological Survey

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 90%

The Selectivity of the Human Placenta in the Transfer of Plasma Proteins From Mother to Fetus

Gitlin¹,

Kumate²,

Urrusti³

et al. 1965

Obstetrical & Gynecological Survey

View full text Add to dashboard Cite

“…It must be emphasized that transplacental IgG transfer is a slow pro cess [34] and requires an intact Fc portion of the IgG mole cule. Gitlin et al's studies [27] demonstrated that when labeled IgG was injected into pregnant women at various intervals before delivery, even after 12 days, the concentra tion in the infant's serum was only about 40% of that in the mother.…”

Section: Discussionmentioning

confidence: 99%

High-Dose Intravenous IgG for the Treatment of Severe Rhesus Alloimmunization

Margulies¹,

Voto²,

Mathet³

et al. 1991

Vox Sanguinis

View full text Add to dashboard Cite

The value of intravenous immunoglobulin (IVIG) in the treatment of 24 severely Rh-sensitized pregnant women was studied. IVIG was infused at a daily dose of 0.4 g/kg maternal body weight for 4-5 consecutive days, and was administered again 15-21 days later until delivery, depending on the evolution of the hemolytic disease. Our population was divided into 3 groups according to the time of onset of therapy: group 1 (n = 8), before 20 weeks’ gestation; group 2 (n = 7), 20-28 weeks, and group 3 (n = 9), after 28 weeks. Initial mean anti-D level was significantly higher in group 1 (25.9 ± 12.9 IU/ml) than in the other 2 groups, whose mean values were, however, higher than 10 IU/ml. Amniotic-fluid total bilirubin levels before the onset of therapy were pathologic, and in 55% of the cases they coincided with zone 3 of Liley’s chart. Hydrops fetalis at the onset of treatment accounted for the only 3 fetal deaths in groups 1 and 2. None of the fetuses developed hydrops during treatment. Six of the 9 neonates in group 3 were depressed at birth (1-min Apgar below 7). However, at 5 min only 1 newborn showed an Apgar below 7. Mean birth weight was over 2,500 g in all the cases. Neonatal hematological condition in group 2 (50% of the babies required only phototherapy) was better than in the other 2 groups (transfusional therapy). There was a significant fall in maternal anti-D titers and intrauterine hemolysis after IVIG treatment. In order to further evaluate the response to IVIG therapy, the 13 cases in our population with a history of fetal/neonatal death in the previous pregnancy were analyzed separately. The results obtained in this particular group of patients demonstrated again the effectiveness of IVIG treatment. Conclusions: There were no adverse effects on the mother or fetus, and there was no need for neonatal intensive care. Results were more favorable if treatment was started before 28 weeks’ gestation in nonhydropic fetuses.

show abstract

“…It has been well established that the only human immunoglobulin trans ferred through the placenta is IgG; IgM and IgA are not [2,4], In ABOincompatible pregnancies, it is evident that in order to be able to relate the potency of the mother's anti-A or -B to the severity of the haemolytic disease of her child, a test is needed which only determines the IgG anti-A or -B of the mother. For the estimation of the IgG titre anti-A or -B in cases of expected ABO-incompatible pregnancies several methods are being used.…”

Section: Introductionmentioning

confidence: 99%

Evaluation of a Simple Method for Determination of IgG Titre Anti-A or -B in Cases of Possible ABO Blood Group Incompatibility

Reesink

Hart

Loghem³

1972

Vox Sanguinis

View full text Add to dashboard Cite

Titres of IgG anti-A or -B in the serum of 64 blood group O women with an obstetrical history of possible ABO blood group incompatibility were examined. Four different 2-mercapto-ethanol (2-ME) techniques varying in time from 3-16 h were evaluated. No definite differences in anti-A or -B titres were observed. When AB substances were used, however, the anti-A or -B titres were on the average 2-3 titration steps lower than in the 2-ME techniques, if demonstrable at all. Besides agglutinating IgG anti-A or -B, haemolysins IgG anti-A or -B could be demonstrated in part of the sera. In 8 sera, the IgG and IgM fractions were separated on sephadex G-200 and treated with 2-ME and AB substances. In the IgG fraction, no definite differences in complete, incomplete and haemolysin anti-A or -B titres were found before and after treatment with 2-ME. Using AB substances, no complete anti-A or -B was found anymore, while the incomplete titres were on the average 2-3 titration steps lower. The anti-A or -B antibody activity of the IgM fraction was completely destroyed by 2-ME and AB substances. From this study we concluded that IgG anti-A or -B could be determined by 2-ME within a few hours and that this technique is much more reliable than the partial neutralization test with AB substances.

show abstract

Étude du passage de la γ-globuline marquée à travers le placenta humain

Cited by 30 publications

References 4 publications

The Selectivity of the Human Placenta in the Transfer of Plasma Proteins From Mother to Fetus

The Selectivity of the Human Placenta in the Transfer of Plasma Proteins From Mother to Fetus

High-Dose Intravenous IgG for the Treatment of Severe Rhesus Alloimmunization

Evaluation of a Simple Method for Determination of IgG Titre Anti-A or -B in Cases of Possible ABO Blood Group Incompatibility

Contact Info

Product

Resources

About